A mouse and cell study links rapamycin with lower atrial fibrillation susceptibility in an accelerated-aging model, pointing to HIF-1α and mitochondrial metabolism. The findings are mechanistic clues, not proof of human benefit or a reason to self-medicate.
Human SFEMG and rodent work in JCI 2026 show sarcopenic weakness can come from postsynaptic NaV1.4 loss at the NMJ, not just wasting. Partial ClC-1 inhibition restored transmission-related force in aged rats; this is not a human drug claim.
Nature Biotechnology embeds six proteomic aging clocks in a phase 2a rentosertib IPF trial. Treated arms show concordant biological-age reductions peaking at week 4, partly dissociated from FVC gains. A dual-purpose design demo, not proof of rejuvenation.
The elderly need autologous stem cell therapy most, yet their stem cells are few and worn out. A 2026 Scientific Reports study briefly treated aged fat-derived stem cells with rapamycin plus nicotinamide, lowering p16, p21 and inflammatory cytokines while restoring differentiation by rebooting the stalled AMPK-mTOR-autophagy loop.
Osteoarthritis is more than wear and tear. An Advanced Science study in mice and human synovium finds that HMGCR, the statin-targeted enzyme of cholesterol synthesis, runs too hot in synovial fibroblasts, overproduces cholesterol, drives cellular senescence, and fuels synovitis and cartilage breakdown; local joint knockdown of HMGCR in mice reverses senescence and eases pain and cartilage loss.
Resveratrol, rapamycin, and diet all claim to fight aging, so why do the effects vary so much? Studies in 2026 show anti-aging interventions succeed or fail depending on sex, life stage, and genetic background, pushing geroscience from a lifespan race toward hallmark-informed prioritization.
Senescent cells pile up because aging immune systems stop clearing them efficiently. Instead of killing every senescent cell, new 2026 reviews argue for senomorphic strategies that quiet SASP-driven inflammation.
Senescent cells have been the bad neighbor of aging biology for nearly two decades. Three 2026 papers flip the question: before we rush to clear them, do we even know what they are? Turns out we barely did — and now that we're learning, the picture is far less black and white.
A blue pill that might protect your brain, and a fiber classification system that's been misleading you for decades. Two stories about how oversimplified categories can steer us wrong.
You took NMN for three months and still look the same in the mirror. Why? Three landmark studies piece together how NAD⁺ collapses with age: how cells fake hypoxia, who eats your supplements, and whether topping NAD⁺ back up can truly rejuvenate old cells.